Eribulin for heavily pre-treated metastatic breast cancer patients

Table 1 Characteristics of patients and tumors in this series

	Median	Range
Age at diagnosis	47	30-73
Age at eribulin treatment	53	34-75
	Patients (n = 21)	%
Hormonal status
ER/ PgR positive	16	76.5
ER/PgR / Her2 negative	5	23.8
Grade
III	12	57.2
II	5	23.8
Unknown	4	19
Performance status
0-1	13	61.9
2-3	8	38.1
Number of metastatic sites
2	3	14.3
More than 2	18	85.7

ER: Estrogen Receptor; PgR: Progesterone Receptor; Her2: Her2/neu oncogene of the EGFR (Epidermal Growth Factor Receptor) family.

Table 2 Eribulin treatment and results

	Median	Range
Progression-free survival (mo)	3	1-14
Overall survival (patients who died)	7	1-18
Follow-up (mo, patients alive)	13.5	7-19
Number of eribulin cycles	3	1-16
	patients (n = 21)	%
Previous lines of treatment
3 or less	8	38.1
More than 3	13	61.9
Reason for eribulin discontinuation
Progression	20	95.2
Adverse effects	1	4.8

All patients in the series had progressed at the time of data collection. Fifteen patients had died at the time of data collection and 6 patients were still alive.

Table 3 Clinical response rates of evaluable patients with metastatic breast cancer treated with eribulin n (%)

	All evaluable patients in the series (n = 18)	95%CI	3 or less previous lines of therapy (n = 8)	95%CI	More than 3 previous lines of therapy (n = 10)	95%CI
CR	0	0	0	0	0	0
PR	7 (38.9)	16.4-61.4	4 (50)	18.7-81.8	3 (30)	1.6-58.4
SD	3 (16.7)	0-33.9	2 (25)	0-55	1 (10)	0-28.6
PD	8 (44.4)	21.5-67.4	2 (25)	0-55	6 (60)	33.2-86.8

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.